MktsMarkets

Theravance Biopharma, Inc.
NASDAQ: TBPHKey statistics
TBPH News
Stories mentioning TBPH from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 17,699 | 45,891 | 19,990 | 26,195 | 15,388 | 18,754 | 16,868 | 14,256 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 5,829 | 7,360 | 8,112 | 10,490 | 11,452 | 9,453 | 9,268 | 9,954 |
| Sales General & Admin | 17,720 | 18,519 | 18,333 | 18,430 | 18,370 | 18,501 | 16,875 | 17,056 |
| Total Operating Expenses | 27,182 | 25,879 | 26,445 | 28,920 | 29,822 | 27,954 | 27,705 | 29,961 |
| Operating Income (Loss) | (9,483) | 20,012 | (6,455) | (2,725) | (14,434) | (9,200) | (10,837) | (15,705) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 3,013 | 3,638 | 4,139 | 1,457 | 939.00 | 904.00 | 1,415 | 1,128 |
| Pretax Income | (6,470) | 73,068 | (2,889) | 73,206 | (14,138) | (8,939) | (10,052) | (15,221) |
| Tax Provision | (1,537) | 12,044 | (6,504) | 18,371 | (559.00) | 6,588 | 2,646 | 1,308 |
| Net Income (Loss) | (4,933) | 61,024 | 3,615 | 54,835 | (13,579) | (15,527) | (12,698) | (16,529) |
| Earnings Per Share (Basic) | (0.10) | 1.20 | 0.07 | 1.09 | (0.27) | (0.31) | (0.26) | (0.34) |
| Earnings Per Share (Diluted) | (0.10) | 1.15 | 0.07 | 1.08 | (0.27) | (0.31) | (0.26) | (0.34) |
| Weighted Average Shares Outstanding (Basic) | 51,279 | 50,317 | 50,520 | 50,177 | 49,706 | 48,847 | 49,038 | 48,747 |
| Weighted Average Shares Outstanding (Diluted) | 51,279 | 51,507 | 51,908 | 50,726 | 49,706 | 48,847 | 49,038 | 48,747 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About TBPH
Theravance Biopharma, Inc. (NASDAQ: TBPH) is a stock listed on the Nasdaq Stock Market under the ticker symbol TBPH. It last traded at $0.0000 (Dec 31, 1969, 7:00 PM ET), unchanged on the day. That gives Theravance Biopharma a market capitalisation of $884.2M and a price-to-earnings ratio of 16.4.
Over the past 52 weeks TBPH has traded between $13.08 and $21.03.
Revenue for the quarter ended Mar 31, 2026 was $17.7M; a net loss of $4.9M. Revenue was up 15.0% from $15.4M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $17.7M | -$4.9M | -27.9% |
| Dec 31, 2025 | $45.9M | $61.0M | 133.0% |
| Sep 30, 2025 | $20.0M | $3.6M | 18.1% |
| Jun 30, 2025 | $26.2M | $54.8M | 209.3% |
From Theravance Biopharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…